Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales ...

Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” ...

Genomics (TXG) closed the last trading session at $8.86, gaining 7.1% over the past four weeks, but there could be plenty of ...

Investors in 10x Genomics Inc (Symbol: TXG) saw new options become available today, for the January 2024 expiration. One of the key data points that goes into the price an option buyer is willing ...

TXG AZTA BLFS EVO NAGE ADPT Company Name 10x Genomics, Inc. Azenta, Inc. BioLife Solutions, Inc. Evotec SE Niagen Bioscience, Inc. Adaptive Biotechnologies Corporation Sector Health Care Health ...

Investors in 10x Genomics Inc (Symbol: TXG) saw new options become available this week, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

10x Genomics TXG shares soared 8.2% in the last trading session to close at $16.99. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption ...

The following article will discuss the smart money sentiment towards 10x Genomics, Inc. (NASDAQ:TXG). Video: Watch our video about the top 5 most popular hedge fund stocks. Hedge funds ...